பாலிசேட் உயிர் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பாலிசேட் உயிர் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பாலிசேட் உயிர் இன்க் Today - Breaking & Trending Today

"The Buzz" Show: Palisade Bio, Inc. (NASDAQ: PALI) FDA Grants Fast Track Designation for LB1148 | Financial Buzz"The Buzz" Show: Palisade Bio, Inc. (NASDAQ: PALI) FDA Grants Fast Track Designation for LB1148


FinancialBuzz.com’s latest
The Buzz Show: Palisade Bio, Inc. Announces FDA Fast Track Designation for its investigational drug LB1148”
Palisade Bio, Inc. (NASDAQ: PALI) surged over 25% in premarket trading after the company announced an FDA Fast Track Designation for the investigational drug LB1148.
LB1148 has the potential to be the first oral treatment to reduce adhesions following abdominal or pelvic surgery, and was previously granted Fast Track Designation for the treatment of postoperative GI dysfunction associated with gut hypoperfusion injury in pediatric patients who have undergone congenital heart disease repair surgery.
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions a ....

Palisade Bio Inc , Buzz Show , Palisade Bio , Track Designation , Fast Track Designation , பாலிசேட் உயிர் இன்க் , புழ்ழ் காட்டு , பாலிசேட் உயிர் , டிராக் பதவி , வேகமாக டிராக் பதவி ,

(PALI) - Palisade Bio Stock Shoots Up On FDA Fast Track Tag For LB1148 For Reduction of Post-Operative Adhesions


LB1148 was previously granted Fast Track Designation to treat postoperative GI dysfunction associated with pediatric cardiovascular surgery.
Phase 2 gastrointestinal surgery trial that will evaluate LB1148 for reducing adhesions, is expected to read out data in 2021.
LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.
By inhibiting the activity of digestive proteases, LB1148 can potentially reduce damage to GI tissues, increase the time to return normal GI function, and shorten the duration of hospital stays.
Price Action: PALI shares are trading 26.1% higher at $6.62 during the premarket session on the last check Thursday. ....

Palisade Bio Inc , Fast Track Designation , பாலிசேட் உயிர் இன்க் , வேகமாக டிராக் பதவி ,